IRIS
VESPASIANI GENTILUCCI, UMBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 10.543
NA - Nord America 4.190
EU - Europa 1.611
SA - Sud America 605
AF - Africa 83
Continente sconosciuto - Info sul continente non disponibili 80
OC - Oceania 26
Totale 17.138
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 7.494
US - Stati Uniti d'America 4.008
CN - Cina 1.257
HK - Hong Kong 813
IT - Italia 790
BR - Brasile 421
BD - Bangladesh 337
VN - Vietnam 272
GB - Regno Unito 211
FR - Francia 203
DE - Germania 127
IN - India 101
CA - Canada 82
AR - Argentina 64
MX - Messico 61
ID - Indonesia 47
FI - Finlandia 44
NL - Olanda 44
TR - Turchia 35
EC - Ecuador 34
UA - Ucraina 31
ZA - Sudafrica 29
CZ - Repubblica Ceca 28
PL - Polonia 28
AU - Australia 25
JP - Giappone 24
ES - Italia 20
CO - Colombia 19
PK - Pakistan 18
SA - Arabia Saudita 18
RU - Federazione Russa 17
IQ - Iraq 16
PH - Filippine 16
CL - Cile 15
PY - Paraguay 15
VE - Venezuela 14
MY - Malesia 13
PE - Perù 11
SE - Svezia 11
CH - Svizzera 9
EG - Egitto 9
JM - Giamaica 9
UZ - Uzbekistan 9
MA - Marocco 8
NP - Nepal 8
TN - Tunisia 7
HN - Honduras 6
TH - Thailandia 6
UY - Uruguay 6
BO - Bolivia 5
ET - Etiopia 5
KE - Kenya 5
LB - Libano 5
NI - Nicaragua 5
AE - Emirati Arabi Uniti 4
BE - Belgio 4
BG - Bulgaria 4
BH - Bahrain 4
DZ - Algeria 4
IE - Irlanda 4
IL - Israele 4
IR - Iran 4
OM - Oman 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
AO - Angola 3
AT - Austria 3
AZ - Azerbaigian 3
BY - Bielorussia 3
CR - Costa Rica 3
CY - Cipro 3
DO - Repubblica Dominicana 3
HU - Ungheria 3
KH - Cambogia 3
KR - Corea 3
KW - Kuwait 3
KZ - Kazakistan 3
LT - Lituania 3
LU - Lussemburgo 3
MD - Moldavia 3
RO - Romania 3
AL - Albania 2
AM - Armenia 2
BA - Bosnia-Erzegovina 2
IS - Islanda 2
JO - Giordania 2
ME - Montenegro 2
MN - Mongolia 2
PA - Panama 2
PR - Porto Rico 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
TL - Timor Orientale 2
XK - ???statistics.table.value.countryCode.XK??? 2
BB - Barbados 1
BJ - Benin 1
BW - Botswana 1
CI - Costa d'Avorio 1
DK - Danimarca 1
Totale 17.040
Salva come PNG Salva come JPEG
Città #
San Jose 1.106
Hong Kong 802
Singapore 800
Ashburn 771
Rome 539
Hefei 392
Beijing 303
Council Bluffs 259
Boardman 217
Columbus 203
Dallas 189
Lauterbourg 172
London 158
Shanghai 138
Santa Clara 127
Ho Chi Minh City 95
Los Angeles 87
New York 71
Munich 62
Hanoi 51
San Francisco 48
São Paulo 48
Mexico City 44
Seattle 36
Brno 28
Toronto 28
Pune 27
Turku 27
Guangzhou 26
Amsterdam 24
Warsaw 23
West Jordan 22
Tokyo 21
Rio de Janeiro 20
Washington 20
Montreal 19
Milan 18
Buffalo 17
Helsinki 17
Chennai 16
Guayaquil 16
Naples 15
Boston 14
Orem 14
Da Nang 13
Haiphong 13
Canberra 12
Johannesburg 12
Charlotte 11
Frankfurt am Main 11
Las Vegas 11
Manchester 11
Sona 11
Brooklyn 10
Chicago 10
Paris 10
Phoenix 10
Riyadh 10
Stockholm 10
Bologna 9
Brasília 9
Lahore 9
Shenzhen 9
Atlanta 8
Curitiba 8
Melbourne 8
New Delhi 8
Quito 8
Denver 7
Hangzhou 7
Hải Dương 7
Kuala Lumpur 7
Tashkent 7
Zhengzhou 7
Bari 6
Biên Hòa 6
Buenos Aires 6
Houston 6
Kyiv 6
Lima 6
Mumbai 6
Pasadena 6
Redmond 6
Secaucus 6
Sydney 6
Thái Bình 6
Thái Nguyên 6
Belo Horizonte 5
Belém 5
Bogotá 5
Cairo 5
Campinas 5
Caracas 5
Florence 5
Istanbul 5
Jakarta 5
Kingston 5
Medellín 5
Nuremberg 5
Poplar 5
Totale 7.556
Salva come PNG Salva come JPEG
Nome #
Altered metal metabolism in patients with HCV-related cirrhosis and hepatic encephalopathy 253
A case of Henoch-Schönlein purpura in the elderly: not just a 'second childhood' 249
A mocking finding: portal cavernoma mimicking neoplastic mass. First sign of myeloproliferative disorder in a patient with Janus kinase2 V617F mutation 243
Advances in management of periprosthetic joint infections: an historical prospective study 237
Deep vein thrombosis, inferior vena cava interruption and multiple thrombophilic gene mutations 234
Angiogenic cytokines in patients undergoing antiviral treatment for chronic hepatitis C virus infection 233
Iloprost: an adjunctive approach to chronic viral hepatitis treatment 232
Breath-print analysis by e-nose may refine risk stratification for adverse outcomes in cirrhotic patients 231
Breath-print analysis by e-nose for classifying and monitoring chronic liver disease: a proof-of-concept study 231
Anti-tumor necrosis factor-alpha reverts growth hormone resistance associated with inflammatory bowel disease 228
Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study 227
METAL HOMEOSTASIS IN PATIENTS WITH PORTO-SYSTEMIC ENCEPHALOPATHY 227
Hepatic expression of lysosomal acid lipase is reduced in non-alcoholic fatty liver disease and inversely associated with the degree of microvescicular steatosis, impairment of the autophagic process and NAFLD activity score 220
Retroperitoneal fibrosis and ankylosing spondylitis: which links? 218
Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C 218
Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia 217
Combined evaluation of aminotransferases improves risk stratification for overall and cause-specific mortality in older patients 217
Granulomatous thyroiditis: an unexpected finding leading to the diagnosis of sarcoidosis 214
Hepatic Lysosomal Acid Lipase and lipophagy in the progression of NAFLD 214
Factors enhancing treatment of hepatitis C virus⇓infected italian people who use drugs: The CLEO-GRECAS experience 213
The hepatic expression of lysosomal acid lipase (LAL) is reduced in NAFLD patients, and associated with features of genetically determined LAL deficiency and NAFLD activity score 210
Impairment of GH/IGF-1 Axis in the liver of patients with hcv-related chronic hepatitis 208
BREATH PRINT ANALYSIS BY E-NOSE IS ASSOCIATED WITH ADVERSE OUTCOMES OF CIRRHOTIC PATIENTS INDEPENDENTLY FROM THE OTHER PROGNOSTIC INDICES 205
Assessment of liver function by the exhaled breath-print during chronic liver disease 205
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 202
THU-390 - Hepatic expression of lysosomal acid lipase is reduced in non-alcoholic fatty liver disease and inversely associated with the degree of microvescicular steatosis, impairment of the autophagic process and NAFLD activity score 175
Cardiotrophin-1 is not associated with carotid or coronary disease and is inversely associated with obesity in patients undergoing coronary angiography 172
Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery 155
Drug–drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients 141
Liver cirrhosis after prolonged therapy with IFN-alpha plus interleukin-2 in a metastatic renal cancer long-term survivor 139
Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination 138
[A 73-year-old woman with vomiting and metabolic alkalosis] 137
Diabetes in chronic liver disease: from old concepts to new evidence 137
Exhaled breath analysis in hepatology: State-of-the-art and perspectives 136
GH-resistance in different stages of chronic liver disease 135
Growth hormone-stimulated insulin-like factor-1 and acid labile subunit in chronic liver disease 135
A challenging alfa-fetoprotein in a cirrhotic patient 133
Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease 131
[A 61-year-old woman with abdominal pain and urination disorders] 127
A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease 124
Association between non-invasive liver fibrosis scores and occurrence of health adverse outcomes in older people 123
METAL METABOLISM IMPAIRMENT IN PATIENTS WITH HEPATIC ENCEPHALOPATHY 122
Portal diameter in the diagnosis of esophageal varices in 266 cirrhotic patients: which role? 118
Determinants of alanine aminotransferase levels in a large population from Southern Italy: relationship between alanine aminotransferase and age 118
Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry 117
[Ramipril and new therapeutic possibilities for ACE-inhibitors] 116
Liver involvement in the course of thymoma-associated multiorgan autoimmunity: The first histological description 114
Biopsy in chronic liver disease: proposal for a shared path between clinicians and pathologists 113
Diagnostic value of Virtual Touch Quantification (VTQ®) for differentiation of hemangiomas from malignant focal liver lesions 111
AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement 111
Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis 110
The PNPLA3 rs738409 variant can increase the risk of liver toxicity in multiple sclerosis patients treated with beta-interferon 110
Donna di 35 anni con febbre, dispnea e dolore alla coscia sinistra [A 35-year-old woman with fever, dyspnea, and pain in the left thigh]. 109
Pain and Frailty in Hospitalized Older Adults 109
A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores 109
Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study 107
Association between clinical scores of liver fibrosis and adverse non-hepatic outcomes: The key in the holistic vision of the patient 106
Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis 101
LIVER TOXICITY IN COLORECTAL CANCER PATIENTS TREATED WITH FIRST LINE FOLFIRI-CONTAINING REGIMEN: A SINGLE INSTITUTION EXPERIENCE 98
Association between non-alcoholic fatty liver disease and cardiovascular disease: a first message should pass 98
An overview of deregulated lipid metabolism in nonalcoholic fatty liver disease with special focus on lysosomal acid lipase 92
Combining genetic variants to improve risk prediction for nafld and its progression to cirrhosis: a proof of concept study 92
Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study 90
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry 86
Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures 80
Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience 79
Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers 78
Lipophagy Impairment Is Associated With Disease Progression in NAFLD 78
IL32 downregulation lowers triglycerides and type I collagen in di-lineage human primary liver organoids 75
Non‐invasive assessment of hepatic steatosis by ultrasound‐derived fat fraction in individuals at high‐risk for metabolic dysfunction‐associated steatotic liver disease 75
Reelin expression in human liver of patients with chronic hepatitis C infection 73
The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen 72
TNF-alpha and growth hormone resistance in patients with chronic liver disease 71
Hepatocellular carcinoma in alcoholic liver disease: current management and recent advances 71
The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen 71
Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis 71
Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD 69
The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients 69
Sarcopenia in Hepatocellular Carcinoma: Pathogenesis and Management 69
Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice 68
Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation 67
Portal inflammation during NAFLD is frequent and associated with the early phases of putative hepatic progenitor cell activation 67
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 66
Poor accuracy and sustainability of the first-step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population 65
Noninvasive Assessment of portal Hypertension in Patients With Primary Biliary Cholangitis is Affected by Severity of Cholestasis 65
Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables 65
Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease 65
Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank 65
Incidence and Outcome of Pneumomediastinum in Non-ICU Hospitalized COVID-19 Patients 65
Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development 62
Identification of matrix metalloprotease 10 (mmp10) as a key new mediator of the regenerative response of the liver 61
Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/C-X-C chemokine receptor 4 axis 61
The Role of Ribavirin in the Combination Therapy of Hepatitis C Virus Infection 59
Infliximab reverses growth hormone resistance associated with inflammatory bowel disease 59
Lysosomal acid lipase activity is reduced both in cryptogenic cirrhosis and in cirrhosis of known etiology 59
Reply to the Letter: “Low levels of transaminase and mortality risk in older people with special reference to sarcopenia” 58
Gas exchanges and pulmonary vascular abnormalities at different stages of chronic liver disease 57
Identification of Fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure 57
Interplay between SIRT-3, metabolism and its tumor suppressor role in hepatocellular carcinoma 57
Machine learning in primary biliary cholangitis: A novel approach for risk stratification 57
Totale 12.687
Salva come PNG Salva come JPEG
Categoria #
all - tutte 106.947
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 106.947
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022336 0 2 8 0 3 3 2 6 46 4 4 258
2022/2023112 12 1 6 4 10 2 30 4 3 5 33 2
2023/2024636 26 50 18 62 61 269 2 37 8 40 20 43
2024/20258.381 131 57 236 45 110 186 143 34 482 562 3.017 3.378
2025/20267.065 620 332 457 810 255 354 1.755 409 534 665 432 442
2026/2027608 135 473 0 0 0 0 0 0 0 0 0 0
Totale 17.138